A 20-month-old boy with infantile leukemia was treated with total body irradiation, etoposide, cyclophosphamide and unrelated cord blood transplantation with a one-antigen mismatch. He relapsed on day 100 and achieved remission after ubenimex administration, and also developed chronic graft-versus-host disease of the skin. He remained in remission for 22 months with repeated courses of ubenimex. Ubenimex may be an alternative to donor lymphocyte transfusion and may be useful for the treatment of a patient who has relapsed after cord blood transplantation.
Unrelated cord blood transplantation (UCBT) has been used worldwide for treatment of acute leukemia due to the ready availability of stem cells and less stringent requirements for HLA identity because of the lower risk of acute and chronic GVHD. There is also a GVL effect during GVHD after cord blood transplantation (CBT).
Leukemia relapsing after transplantation is likely to be refractory to treatment. Immunotherapy in the form of donor lymphocyte transfusion (DLT) is one of the treatment approaches for relapsed patients and may induce a GVL effect. However, there is generally no donor available for DLT in patients who have undergone UCBT although some patients who have relapsed after BMT achieve a remission with the GVL effect which follows discontinuation of CYA.
1,2
Ubenimex is a dipeptide with a molecular weight of 303.30 that inhibits aminopeptidase N. It is clinically used as a biologic response modifier for leukemia through augmentation of the host immune system by stimulating the production of IL-1 and IL-2 by mononuclear cells 3 and increasing natural killer (NK) activity. 4 Hiraoka et al reported that ubenimex may decrease the rate of leukemic recurrence via the GVL effect associated with chronic GVHD in patients who have undergone BMT. We describe a patient in whom leukemia recurred after UCBT but who achieved complete remission with induction of GVHD and a GVL effect using ubenimex. This case report demonstrates that ubenimex is a drug that may be useful for the treatment of recurrent leukemia after CBT as an alternative to DLT.
Case report
A 20-month-old male was diagnosed as having infantile leukemia at the age of 6 months. His initial WBC was 79.4 ϫ 10 9 /l with 96% blasts. Central nervous system disease and an abdominal mass were present. The blasts were classified as AUL according to the FAB classification and were positive for CD3, CD4, 7, 13, 33, 34 with no MLL rearrangement, and cytogenetics were 47, XY, +19. Following chemotherapy with vincristine, doxorubicin, cyclophosphamide, etoposide, high-dose cytarabine, dexamethasone, intrathecal methotrexate, Ara-C, and hydrocortisone, the patient achieved complete remission within 9 months after diagnosis, which continued for 6 months with chemotherapy.
Stem cell transplantation was indicated for the refractory infantile leukemia. Since there were no HLA-matched donors in the patient's family, cord blood was obtained from a cord blood bank and a one-antigen mismatched UCBT was undertaken (Table 1) . Conditioning consisted of Table 1 Characteristics of donor cord blood and patient fractionated total body irradiation (12 Gy in six fractions given twice daily from days Ϫ7 to Ϫ5) followed by etoposide 60 mg/kg by continuous i.v. on day Ϫ4 and cyclophosphamide 60 mg/kg once daily i.v. on days Ϫ3 and Ϫ2. GVHD prophylaxis was with methylprednisolone (mPSL), 1 mg/kg/day from day 0 to day +4 and then 2 mg/kg/day, and 5 mg/kg/day CYA starting on day Ϫ1, with a target trough of 150 to 250 ng/ml. The only complication was grade I skin acute GVHD. An absolute neutrophil count greater than 0.5 ϫ 10 9 /l was achieved on day 20, and reticulocytes had increased to more than 20% by day 63. Platelets were transfusion-dependent. A bone marrow examination on day 64 revealed donor chimerism as indicated by XX 97.3% on FISH.
Donor Patient
On day 100, when the CYA trough value was 120ෂ150 ng/ml and mPSL was 1 mg/kg/day, a bone marrow examination revealed 52.8% blast cells with the same surface markers as those at the initial diagnosis and XY 75.2% by FISH. Disease relapse was diagnosed, and CYA and mPSL were discontinued. However, some days later 12% blast cells were present in the peripheral blood. Oral ubenimex at 15 mg daily was started to generate a GVL effect. Two days later, a fever of 39.5 to 41°C appeared and an itchy rash spread from the limbs to the entire body with partial epidermolysis. These were considered to be manifestations of grade IV GVHD. The bone marrow blasts had decreased to 11.4% by day 8 after the start of the ubenimex, and this was discontinued. The blasts had disappeared from the peripheral blood by day 17, and a bone marrow examination confirmed a second remission with blast cells at 0.2%, and XX 99.2% by FISH on day 21 after the start of ubenimex administration. Following discontinuation of the ubenimex the patients body temperature returned to about 38°C and his rash abated, and no treatment was therefore given for GVHD. About 1 month after discontinuation of the ubenimex his skin was partially depigmented, and there was mild epidermolysis of the face and dry skin over the entire body. The itching had resolved. Mild elevations in ALP and ␥GTP were present. At the same time, hematopoietic reconstitution occurred. To continue the GVL effect, ubenimex was administered until grade IෂII GVHD appeared, at intervals of 6 to 8 weeks. During the next three courses, grade I GVHD occurred and persisted for about 1 week after the starting the drug. However, after the fifth course, GVHD did not develop with the same dose, and the dose of ubenimex was therefore increased to 30 mg daily and the administration period extended to 2 weeks. Despite the increase on dose and extension of the treatment period, no GVHD occurred. His state of remission continued for 12 months, and the treatment was concluded after a total of seven courses. At present, the patient has dry skin and anhidrosis of the trunk, where the initial skin GVHD occurred, but there is no gut GVHD, oral sicca, or dry eyes. The patient's second remission has continued for 22 months, and he is doing well with a Karnofsky score of 90%.
Immunological examination showed no marked changes in CD 4/8 ratios and percentages of CD56 + cells before and after the courses of ubenimex. The percentage of CD3 +
HLA-DR
+ cells was decreased from about 60% after administration of ubenimex to 5%, independent of the courses of ubenimex.
Discussion
CBT is an acceptable alternative to bone marrow as a source of stem cells. Although there is some concern that the GVL effect may be insufficient because GVHD is diminished after CBT, an increased risk of leukemia relapse in patients given CBT has not been shown. 6 Treatments for patients with leukemic relapse after stem cell transplantation include chemotherapy, a second stem cell transplant, cytokine treatment and immunotherapy. DLT has been reported to be effective in patients with chronic phase CML but does not seem to be effective for most patients with acute leukemia. 7 However, in patients receiving cord blood transplants, donor cells are difficult to obtain.
It has also been reported that discontinuation of CYA induces a GVL effect and allowing a complete remission in some patients who have relapsed after BMT.
1,2 Howrey et al 8 reported that discontinuation of CYA, and G-CSF administration generate a GVL effect, which can be powerful enough to induce complete remission in patients who relapse after UCBT. Immunotherapy is not always durable, and relapse continues to occur very late. 9 The induction and continuation of a GVL effect is necessary for successful treatment of leukemia recurrence. The effector cells in the GVL effect are thought to be T cells, NK cells and lymphokine-activated killer (LAK) cells. NK cells and LAK cells in the cord blood respond to IL-2 in particular and mediate high cytotoxicity. 10 We successfully treated leukemia relapse after UCBT with ubenimex which is an immunomodulator involved in inhibition of the degradation or processing of cytokines. If sufficient GVL effect is not generated by discontinuation of immunosuppressants, ubenimex may help to generate a GVL effect, and repeated courses of ubenimex treatment may enable continuation of the GVL. If there is no donor available for DLT, ubenimex may be an alternative to DLT. Further study with more cases is required to determine the effectiveness of ubenimex in CBT. 
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